Dr. Randall J. Bateman, MD
Neurology (Neurology Physician)
4921 Parkview Pl, Div Neuro Aging And Dementia, Ste 6c
Saint Louis, MO 63110
- Medicare participating
At a glance
- Medical school
- Clvlnd Clinic Lerner College of Med of Case Wstn Rsv University (2000)
- Years since graduation
- 26
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 16
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2000Medical school: Clvlnd Clinic Lerner College of Med of Case Wstn Rsv University
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
MO license 2004008546
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Barnes Jewish Hospital Saint Louis, MO
- Missouri Baptist Medical Center Saint Louis, MO
Medical groups
- Washington University (3,029 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 16
- Services billed
- 42
- Patients’ average age
- 78
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Escitalopram Oxalate Other prescribers in Saint Louis, MO | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 4 payments worth $40,000 in total to this clinician.
| C2n Diagnostics, LLC | $40,000 |
|---|
| Compensation for services other than consulting (speaking, faculty) | $40,000 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| C2n Diagnostics, LLC Mar 31, 2025 | Compensation for services other than consulting (speaking, faculty) PRECIVITYAD2 · ALZHEIMER'S DISEASE | $10,000 |
| C2n Diagnostics, LLC Jun 30, 2025 | Compensation for services other than consulting (speaking, faculty) PRECIVITYAD2 · ALZHEIMER'S DISEASE | $10,000 |
| C2n Diagnostics, LLC Sep 30, 2025 | Compensation for services other than consulting (speaking, faculty) PRECIVITYAD2 · ALZHEIMER'S DISEASE | $10,000 |
| C2n Diagnostics, LLC Dec 31, 2025 | Compensation for services other than consulting (speaking, faculty) PRECIVITYAD2 · ALZHEIMER'S DISEASE | $10,000 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $2,974,596 in research payments for these studies, mostly to the institutions running them.
- A Phase IIIb/IV Open-Label Study of Lecanemab to Evaluate Prevention and Progression of Dominantly Inherited Alzheimer’s Disease
Eisai Inc. - A Phase II/III Randomized, Double-Blind, Placebo-Controlled Multi Center Study of 2 Potential Disease Modifying Therapies in individuals at Risk for and with Dominantly Inherited Alzheimer's Disease
F. Hoffmann-la Roche AG - Neurofilament Light Chain (NfL) Research Consortium Agreement
F. Hoffmann-la Roche AG
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.